We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
-$193M
Cap. Flow %
-7.88%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 63.96%
2 Consumer Discretionary 16.48%
3 Technology 3.08%
4 Real Estate 0.36%
5 Communication Services 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$335M 13.68%
60,240,864
– –
WW
2
DELISTED
WW International
WW
$299M 12.19%
14,818,300
– –
MRNA icon
3
Moderna
MRNA
$21.9B
$102M 4.16%
5,006,298
-250,000
-5% -$4.64M
ONC
4
BeOne Medicines Ltd
ONC
$33.9B
$79.2M 3.23%
600,000
– –
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$76.8M 3.14%
1,650,000
+600,000
+57% +$26.3M
NVDA icon
6
NVIDIA
NVDA
$4.64T
$75.4M 3.08%
+16,800,000
New +$65.2M
BABA icon
7
Alibaba
BABA
$275B
$75.2M 3.07%
412,000
– –
CELG
8
CALL
DELISTED
Celgene Corp
CELG
$70.8M 2.89%
750,000
-250,000
-25% -$21.9M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$68M 2.78%
850,000
+250,000
+42% +$18.5M
BAC icon
10
CALL
Bank of America
BAC
$433B
$55.2M 2.25%
2,000,000
-2,500,000
-56% -$70.7M
RUBY
11
DELISTED
Rubius Therapeutics, Inc
RUBY
$52.6M 2.15%
2,908,791
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$48.8M 1.99%
2,000,000
-500,000
-20% -$10.4M
GS icon
13
CALL
Goldman Sachs
GS
$293B
$48M 1.96%
250,000
– –
ATRA icon
14
Atara Biotherapeutics
ATRA
$70.4M
$45.7M 1.87%
46,000
+6,000
+15% +$5.57M
SRRK icon
15
Scholar Rock
SRRK
$5.88B
$44.1M 1.8%
2,346,040
+50,000
+2% +$880K
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$38.4B
$42.1M 1.72%
450,000
-50,000
-10% -$4.18M
GM icon
17
CALL
General Motors
GM
$82.5B
$37.1M 1.51%
1,000,000
-2,500,000
-71% -$95M
GOSS icon
18
Gossamer Bio
GOSS
$91.2M
$36M 1.47%
+1,658,968
New +$34.6M
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$35.4M 1.44%
2,600,000
-400,000
-13% -$4.89M
FATE icon
20
Fate Therapeutics
FATE
$267M
$31.6M 1.29%
1,800,000
-350,000
-16% -$5.52M
IFRX icon
21
InflaRx
IFRX
$253M
$31.2M 1.27%
825,000
+325,000
+65% +$12.1M
BMY icon
22
CALL
Bristol-Myers Squibb
BMY
$130B
$31M 1.27%
650,000
+100,000
+18% +$4.98M
NKTR icon
23
Nektar Therapeutics
NKTR
$2.35B
$30.2M 1.23%
60,000
+6,667
+13% +$3.95M
AGIO icon
24
Agios Pharmaceuticals
AGIO
$2.09B
$27M 1.1%
400,000
– –
ARGX icon
25
argenx
ARGX
$55.1B
$25M 1.02%
200,000
-70,000
-26% -$8.23M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group withdrew a net $193M in Q1 2019, closing 19 positions and reducing 18 holdings. Its most notable exit was Clementia Pharmaceuticals Inc., an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in NVIDIA worth $75.4M.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.